The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. - Wikidata - wikimedia - TriplyDB

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

http://www.wikidata.org/entity/Q37141163

about

Herpes Zoster: the rationale for the introduction of vaccination in Italy Evaluation of efficacy and effectiveness of live attenuated zoster vaccine Varicella vaccination in Europe - taking the practical approach.Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.Treatment considerations for elderly and frail patients with neuropathic pain Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study.Herpes zoster is associated with prior statin use: a population-based case-control study.Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study.Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study.ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?Assessment of vaccine candidates for persons aged 50 and older: a review.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.The humanistic, economic and societal burden of herpes zoster in Europe: a critical review Tumor necrosis factor blockade and the risk of viral infection Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.Awareness, Knowledge, and Vaccine Acceptability of Herpes Zoster in Korea: A Multicenter Survey of 607 Patients Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study.Balancing the Efficacy and Safety of Vaccines in the Elderly.Abdominal pain in an adult with Type 2 diabetes: A case report.Herpes zoster eye complications: rates and trends Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response.Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.Postherpetic neuralgia: from preclinical models to the clinic.Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study.Treatment of the localized pain of postherpetic neuralgia.Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly.Complications of herpes zoster in cancer patients.Chronic pain patients' treatment preferences: a discrete-choice experiment.Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases.Functional decline and herpes zoster in older people: an interplay of multiple factors.Prevention of herpes zoster pain.Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy.Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.PainVision® Apparatus for Assessment of Efficacy of Pulsed Radiofrequency Combined with Pharmacological Therapy in the Treatment of Postherpetic Neuralgia and Correlations with Measurements.Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

P2860

Q26770662-1978B73D-B231-48E6-A330-BA5935C6D7AE Q26866473-E289F72C-6397-4B92-A6DF-BCB0F9D528AB Q33454919-99AF765D-A9C3-4A96-8C33-C560FCC1ED9A Q33602005-B6E71D68-E616-4407-BBFD-24760325EA1B Q33611436-6DA4C217-F51C-4D5B-96C2-6F3C4CD8DE12 Q33657323-352A7C2B-0DA7-43B4-83E7-3D48A6AD0F49 Q33747265-234C8B9E-6B0C-4274-AC11-48F91BF6E278 Q33776676-0CBA87E5-DA66-42CF-BCCE-613F6AB83E41 Q34101345-081EBE33-6BF3-4B2C-AAD0-2DC635A35B71 Q34400948-970065D0-0029-496E-BD91-9825D75ABF3B Q34461800-B6388105-973B-495F-9225-1109315CE55C Q34468957-52425F0F-4ABD-468C-82C0-E6CD9757FBCD Q34667569-F6868C62-35A7-46CF-9F7C-CB675EA53934 Q34668826-CA4C8E3E-E01D-48FC-8752-1D33F356A86B Q35000186-07E2A5AF-C7B3-45E4-AD76-68C38E328AE1 Q35147612-278C470A-AC90-4CA4-B57D-E24BC071F8FC Q35161630-4E106773-2DAD-43BF-A04E-370F45729606 Q35667362-DF7A18B6-BAC7-42E7-B089-BC1543BEC3C2 Q35826062-AC2760DD-DA65-4741-ACCC-0C35C3690DA4 Q36214230-30A5AEF6-5A9F-4B22-90C3-0D4C8FDDD3D6 Q36602847-DD7031FA-DED0-4CFD-9959-8FE9570E64BD Q36740019-4E6936DE-2739-4EFE-8956-516E60678D7C Q36916061-3EB81BA7-D61C-4A67-968E-22031EA46926 Q37211248-28CC01AE-A3B8-44AF-8346-EAC4AB223448 Q37461377-9B0189AC-78EF-4AD8-BCFA-52FE3257ABB8 Q37521902-6D8A113E-EEFF-48C4-98EA-574C27044737 Q37605345-42D3D20C-3AEB-4593-BC3A-36E4EBBA7461 Q37669420-306618D7-C3B9-4D95-A92A-892191E3F251 Q37682548-5A33AD94-0108-4C07-8D3C-FEDE85A87406 Q37825610-139A966D-62AC-42F6-9B0F-E90CA799EEB0 Q38209370-142AB432-0110-4DC2-83CC-6E0B24110E65 Q38221971-52291A67-29C5-4610-B27B-19EFF8390DBE Q38303228-E164E8EC-7FDC-4966-A71A-816A739BBF3E Q38600346-DC073D5F-A790-41EA-A02D-943412FD1AF8 Q39254009-A248F01B-2A64-4FC3-A2F7-AB8E9C9FCA64 Q39750613-93AE2594-C26F-45B4-A237-FDD85A92738A Q40437635-7CB06875-033A-4B8A-AFA8-407430C046C7 Q41883038-6216E254-A9BA-48B5-8BA0-95CAAF029723 Q42281395-A617809F-3046-419D-AF7A-AEE6A4CB0000 Q46941948-ECAB1656-0AFD-4996-B48F-B1BA6C1CE85E

P2860

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

http://www.wikidata.org/entity/Q37141163

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@en

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@nl

type

label

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@en

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@nl

prefLabel

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@en

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@nl

P1433

Q37141163-62F1A50B-D0F1-465D-8D28-5B30E1E82054

P1476

Q37141163-3A97161C-DF15-47F6-BB2B-A13B29155310

P2093

Q37141163-1A795C62-DC1A-4030-B8CE-FC47A981666F

Q37141163-29C28680-44BE-4A88-9D11-674532636E70

Q37141163-E17C1D34-17A7-4BB2-A549-7737F3DA517F

P2860

Q37141163-043464D3-3523-4628-A375-D8CDFEA9ED0B

Q37141163-121041F6-C08A-40B9-A3DF-CB416E19BD65

Q37141163-1EC5F559-4526-4067-8556-69ED46E27614

Q37141163-27CAF05B-8FB0-4525-895D-84C0FCE19415

Q37141163-327FE839-D55A-4B9F-B4AC-1CDE83F4BD81

Q37141163-33FB44FA-5ECE-414E-B8BD-1017231DA87E

Q37141163-414F9BEF-3039-4D17-9B72-4CBF44128083

Q37141163-436E7B41-2ACE-4159-A48D-3A307E4D4118

Q37141163-4BADA440-3CFC-47FE-A9D1-E598F063FADB

Q37141163-4D9DBABF-9EB6-4973-B63F-8E465BBE01A3

P304

Q37141163-FE1B9521-0A54-4AB1-A25A-E8818F093416

P31

Q37141163-1BF14487-B992-44E2-B088-2758B0912693

P356

Q37141163-5CBFF379-3029-4650-8612-D7ED2CC646D9

P407

Q37141163-035BA6D0-16A0-4371-BA4E-194F26AE908F

P478

Q37141163-9B3ABFEA-E820-4B2D-AD22-4BB60C07E9C0

P577

Q37141163-F580870E-7BAA-4E47-BCBD-9C15C85639A5

P5875

Q37141163-7920DA9C-F8C8-4022-9AD2-FDD8EEC59827

P698

Q37141163-365B1F1F-6BF3-4024-865D-1ED541824472

P921

Q37141163-0C365F4D-FBFF-4745-B0ED-FAE859235367

P356

P1433

The Journal of Infectious Diseases

P1476

The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.

@en

P2093

C Peter Watson

http://www.w3.org/2001/XMLSchema#string

John W Gnann

http://www.w3.org/2001/XMLSchema#string

Kenneth Schmader

http://www.w3.org/2001/XMLSchema#string

P2860

The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003

The incidence of herpes zoster in a United States administrative database

Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up

What does epidemiology tell us about risk factors for herpes zoster?

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

Herpes zoster itch: preliminary epidemiologic data.

The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial.

P304

S207-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/522152

http://www.w3.org/2001/XMLSchema#string

P407

P478

197 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5434071

http://www.w3.org/2001/XMLSchema#string

P698

18419399

http://www.w3.org/2001/XMLSchema#string

P921